Molecular structure of Gemfibrozil, CAS Number: 25812-30-0
Gemfibrozil (CAS 25812-30-0)
See product citations (2)
Alternate Names:
2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic aci
Application:
Gemfibrozil is a hyperlipidemic agent
CAS Number:
25812-30-0
Purity:
≥98%
Molecular Weight:
250.33
Molecular Formula:
C15H22O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Gemfibrozil is a synthetic compound derived from fibrin, a naturally occurring fatty acid. It is a hyperlipidemic agent that elevates plasma HDL and lowers triglycerides and LDL by stabilizing apoA-I mRNA transcripts. Gemfibrozil has garnered substantial attention in scientific research, serving various purposes. In vitro studies have delved into the molecular mechanisms underlying gemfibrozil′s actions and its effects on diverse cell types.
Gemfibrozil (CAS 25812-30-0) References
- Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more. | Doggrell, SA. 2001. Expert Opin Pharmacother. 2: 1187-9. PMID: 11583069
- Gemfibrozil-induced myopathy. | Magarian, GJ., et al. 1991. Arch Intern Med. 151: 1873-4. PMID: 1888257
- Interaction between gemfibrozil and warfarin: case report and review of the literature. | Dixon, DL. and Williams, VG. 2009. Pharmacotherapy. 29: 744-8. PMID: 19476425
- Gemfibrozil, stretching arms beyond lipid lowering. | Roy, A. and Pahan, K. 2009. Immunopharmacol Immunotoxicol. 31: 339-51. PMID: 19694602
- Gemfibrozil-induced impotence. | Pizarro, S., et al. 1990. Lancet. 336: 1135. PMID: 1978015
- Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. | Tornio, A., et al. 2017. Expert Opin Drug Metab Toxicol. 13: 83-95. PMID: 27548563
- Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. | Kim, K., et al. 2017. Orphanet J Rare Dis. 12: 113. PMID: 28623936
- Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. | Todd, PA. and Ward, A. 1988. Drugs. 36: 314-39. PMID: 3056692
- Gemfibrozil derivatives as activators of soluble guanylyl cyclase - A structure-activity study. | Gayler, KM., et al. 2021. Eur J Med Chem. 224: 113729. PMID: 34365128
- Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges. | Shah, MB. 2022. Biomolecules. 12: PMID: 36139056
- Gemfibrozil-Induced Intracellular Triglyceride Increase in SH-SY5Y, HEK and Calu-3 Cells. | Bachmann, CM., et al. 2023. Int J Mol Sci. 24: PMID: 36769295
- Gemfibrozil-lovastatin-associated myalgia. | Rosenson, RS. 1993. Am J Cardiol. 71: 497. PMID: 8498994
- Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. | Spencer, CM. and Barradell, LB. 1996. Drugs. 51: 982-1018. PMID: 8736620
Inhibitor of:
ABCD1, ABCG5, ABHD3, ACOT12, ACOT2, ACOT4, ACOX3, ACSM5, ACSVL3, Angptl3, Angptl5, Angptl7, apoA-IV, apoAL, apoB48R, apoC-III, apoC1, apoE, ApoER2, APOL (Apolipoprotein L), apoL-VI, apoM, APOP1, BSA, C20orf79, Ces1a, CYB5R1, Cyp2c54, CYP2C8, CYP2C9, Cyp3a44, Cyp3a57, Cyp3a59, Cyp4f13, DDHD2, DECR1, DSCD75, EBPL, ECH1, ECHS1, EG226601, EG624219, EG625716, EG666803, Endothelial Lipase, FA2H, GGPL-I, GNPAT, GRAMD1A, HACL1, Hepatic Lipase, ILBP, LCAT, LDL, LDLRAD2, LIP1, Lmf1, LPAAT-δ, LPAAT-ε, MATE1, mitoNEET, NTCP, OATP-A, OATP-C, OATP-F, OATP-H, OATP-I, OATP-J, Oatp2, Oatp3, Oatp5, Olr235, Olr403, Olr424, PDSS2, PECR, Peroxin 1, Peroxin 11α, Peroxin 11β, Peroxin 13, Pex13p, Pex14p, Pex5p, PHYHIPL, Plb3, PNPLA1, SCP-2, SEC14L2, SEC14L4, SgK223, SLC22A29, Slco6c1, Slco6d1, STARD, StARD10, UGT1A10, UGT1A2, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A8, UGT2A3, UGT2B, UGT2B1, VDR, and XKR4.Activator of:
17β-HSD11, 2900097C17Rik, AADACL1, AADACL2, ABCD2, ABHD10, ACAD-8, ACADSB, ACOT5, ACOX2, ACSBG2, ACSL1, apoC-I, apoC-II, apoC-IV, Carnitine Acetyltransferase, Ces1d, Ces1g, CES2, Ces3b, Cholesterol Esterase, CPTII, Cyp2c54, Cyp2c69, CYP2D40, CYP4A1, CYP4A11, CYP4A22, CYP4A32, Cyp4f39, DECR2, DSCD75, E-FABP, EHHADH, FACL5, fetuin-A, GK3P, GPIHBP1, H2-Q10, LDLRAD4, LOC730005, LPD lipase, LPL, OAT, OATP16, Oatp2, OATP8, PAP-2b, Peroxisome 26, PLTP, Pmp24, PPAR alpha, pUb-R, SCP2D1, SEC14L3, Sodium Taurochenodeoxycholate, SR-B1, TBL2, TYSND1, and ZNF202.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Gemfibrozil, 5 g | sc-204764 | 5 g | $65.00 | |||
Gemfibrozil, 25 g | sc-204764A | 25 g | $262.00 |